Novartis wins US OK for biosimilar version of Amgen's Enbrel

U.S. regulators have approved the first near-copy of Enbrel, drugmaker Amgen's pricey biologic medicine for treating rheumatoid arthritis and other immune system disorders.

The follow-up version of Enbrel, dubbed Erelzi, was developed by Swiss drug giant Novartis, which would not disclose the planned list price for Erelzi.

Novartis also couldn't say when the new medicine will be launched by its Sandoz unit, which makes and "biosimilars"—nearly identical versions of produced in living cells.

Erelzi is the third biosimilar drug approved by the Food and Drug Administration. It's also the second approved biosimilar developed by Novartis, and the second that will compete with an Amgen drug.

Enbrel was first approved in 1998. It can cost about $4,000 per month without insurance.

Explore further

Lower-cost biotech drug gets thumbs up from FDA panel (Update)

© 2016 The Associated Press. All rights reserved.

Citation: Novartis wins US OK for biosimilar version of Amgen's Enbrel (2016, August 30) retrieved 21 April 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments